(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 81.64% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Zymeworks's revenue in 2026 is $37,127,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $22,193,921,808, with the lowest ZYME revenue forecast at $17,044,409,688, and the highest ZYME revenue forecast at $29,621,935,155. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $15,975,763,519, with the lowest ZYME revenue forecast at $9,109,747,360, and the highest ZYME revenue forecast at $26,799,886,141.
In 2028, ZYME is forecast to generate $17,379,337,306 in revenue, with the lowest revenue forecast at $11,120,022,657 and the highest revenue forecast at $27,120,621,910.